Cargando…
Radiotherapy and Erlotinib Combined: Review of the Preclinical and Clinical Evidence
Epidermal growth factor receptor (EGFR) is often overexpressed in tumors and has been associated with poor prognosis in some cancer types. The introduction of inhibitors of EGFR, such as erlotinib, represents an important recent advance in the targeted treatment of cancer. Several studies have evalu...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Research Foundation
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355822/ https://www.ncbi.nlm.nih.gov/pubmed/22645717 http://dx.doi.org/10.3389/fonc.2012.00031 |